Viral Genetics' HIV Drug Confirms Antiviral Activity
Posted on: Tuesday, 20 June 2006, 12:00 CDT
Viral Genetics' investigational anti-HIV therapy VGV-1 has posted positive results in a 137-patient clinical trial conducted in South Africa. Results confirmed immunological bioactivity and antiviral properties while also suggesting that the optimal dose has not yet been identified and requires further study.
Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load at day 150 that diminished at day 240.
Additionally, in aggregate, VGV-1 treated patients demonstrated positive changes in immune markers associated with HIV infection and proviral peripheral blood mononuclear cells (PBMCs). Proviral PBMCs are cells that have been infected with HIV and produce additional copies of the virus.
"This is the first placebo-controlled study of VGV-1 and confirms the biological activity of the product. We are encouraged by the results as they appear to be consistent with those of our four previous clinical trials," said Harry Zhabilov, executive vice president of R&D for the company.
Source: Datamonitor
Related Articles
- Bristol-Myers Squibb Reports Encouraging Results From HIV Study
- Genetic Immunity Reports Positive Results of HIV Immune Therapy
- Puzzling Results From HIV Vaccine Trial
- Police Investigate Security Breach of Patient Records in N.L.
- Progenics Presents Additional Positive Clinical Results for HIV-Entry Inhibitor PRO 140 at International AIDS Meeting
- Incyte to Report Positive Preliminary Clinical Results From HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JPMorgan Healthcare Conference
- Fast Results on HIV Tests Ease Anxiety: Experts Hope More at-Risk People Will Find Out Whether They Are
- Merck Announces Interim Results From Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor
- Pfizer Abandons Development of Two Drugs
- HIV-TB Co-Infection: Epidemiology, Diagnosis & Management
 |
 |
User Comments (0)
RSS Feeds